EUVIMEDOntdek EUVIMED
Open access

Ionizable Cholesterol‐Integrated Lipid Nanoparticles for Efficient siRNA Delivery to Solid Tumors

Suyoung Kang iD, Duc-Toan Nguyen iD, Sangyong Jon iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.70464 ↗

At a glance

Journal article in ChemMedChem, 2026. Written by Suyoung Kang and 2 co-authors. Institution: Department of Biological Sciences, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic …. Major MEDLINE topics: RNA, Small Interfering, Cholesterol, Nanoparticles, Lipids. 34 references. The full text is freely available in PubMed Central. Funded by: National Research Foundation of Korea.

SamenvattingSubjectsBibliografische gegevensCiteRelated studies

Abstract (original language)

Lipid nanoparticles (LNPs) are clinically validated platform for the delivery of small interfering RNA (siRNA) therapeutics. However, conventional LNPs typically consist of multiple lipid components, which complicates formulation optimization and limits compositional flexibility. Furthermore, efficient delivery of siRNA to extrahepatic tissues, including solid tumors, remains a major challenge. To address these limitations, we developed a class of ionizable cholesterol derivatives by conjugating biocompatible dimethylated amino acids to cholesterol through a cleavable linker, thereby integrating the structural role of cholesterol and the pH‐responsive ionization of ionizable lipids into a single molecule. Five i‐Chol derivatives were synthesized and formulated into LNPs, which demonstrated efficient siRNA encapsulation and delivery in cancer cells. The resulting siRNA@i‐Chol LNPs exhibited uniform particle size and near‐neutral surface charge, indicating favorable physicochemical properties for systemic administration. Notably, phenylalanine‐based cholesterol LNPs (Phe‐Chol LNPs) loaded with siRNA targeting kinesin spindle protein (KIF11) achieved the most potent in vitro gene knockdown in PC3 prostate cancer cells and induced significant dose‐dependent antitumor activity in a xenograft model without observable systemic toxicity. Collectively, this study establishes a simplified i‐Chol LNP platform that maintains high siRNA delivery efficiency to solid tumors and provides a versatile framework for further LNP engineering and scalable manufacturing.

Subjects

MeSH terms (MEDLINE)

RNA, Small InterferingCholesterolNanoparticlesLipidsAntineoplastic AgentsHumansAnimalsKinesinsParticle SizeMaleMiceMice, NudeCell ProliferationPC-3 CellsDrug Screening Assays, AntitumorMolecular StructureLiposomes

Author keywords

cancer therapydrug deliveryionizable cholesterollipid nanoparticles (LNPs)siRNAs

Substances

RNA, Small InterferingCholesterolKinesinsKIF11 protein, humanLipidsAntineoplastic AgentsLipid NanoparticlesLiposomes

Authors and institutions

  • Department of Biological Sciences, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
  • Center for Precision Bio-Nanomedicine, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.

ORCID profiles: Suyoung Kang, Duc-Toan Nguyen, Sangyong Jon

Funding

  • National Research Foundation of Korea

Cite

APA

Kang, S., Nguyen, D. T., & Jon, S. (2026). Ionizable Cholesterol‐Integrated Lipid Nanoparticles for Efficient siRNA Delivery to Solid Tumors. ChemMedChem. https://doi.org/10.1002/cmdc.70464

Vancouver

Kang S, Nguyen DT, Jon S. Ionizable Cholesterol‐Integrated Lipid Nanoparticles for Efficient siRNA Delivery to Solid Tumors. ChemMedChem. 2026. doi:10.1002/cmdc.70464

BibTeX
@article{Kang2026,
  author = {Kang, Suyoung and Nguyen, Duc-Toan and Jon, Sangyong},
  title = {Ionizable Cholesterol‐Integrated Lipid Nanoparticles for Efficient siRNA Delivery to Solid Tumors},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70464}
}
Start for free →